CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 24 enrolled
Drug / intervention
filgrastim +5 morebiological
Likely dose
Not stated in record
Key inclusion· 8
  • Histologically confirmed primary CNS pure germ cell tumor diagnosed within the past 31 days
  • Age 3 to 25 years
  • Localized disease (M0) or disseminated disease (M+) meeting specific staging criteria
  • Serum β-HCG ≤ 50 IU/dL, serum AFP ≤ 10 IU/L and ≤ institutional norm, CSF AFP ≤ 2.0 IU/L and ≤ institutional norm
Key exclusion· 1
  • Prior chemotherapy, radiotherapy, or other therapy for germ cell tumor (prior surgery allowed)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00085098
NCT00085098Phase 3Completed

Radiotherapy Alone Versus Chemotherapy Followed By Response-Based Radiotherapy For Newly Diagnosed Primary CNS Germinoma

Children's Oncology Group·interventional·Posted Jun 11, 2004·Updated Sep 7, 2018

In Brief

A Phase 3 clinical trial evaluating filgrastim, carboplatin, and 4 other interventions for Brain Tumor and Central Nervous System Tumor. Completed, enrolled 24 participants across 107 sites in 4 countries.

Detailed Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether radiation therapy alone is as effective as chemotherapy plus radiation therapy in treating germ cell tumor. PURPOSE: This randomized phase III trial is studying radiation therapy alone to see how well it works compared to chemotherapy and radiation therapy in treating patients with newly diagnosed primary CNS germ cell tumor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Canada, Puerto Rico, United States

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 11, 2004
Enrollment StartJan 1, 2007
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 22.1 years ago

Interventions

filgrastimbiological

Given by infusion or injection

carboplatindrug

Given IV over 1 hour

cisplatindrug

Given IV over 6 hours

cyclophosphamidedrug

Given IV over 1 hour

etoposidedrug

Given IV over 2 hours

radiation therapyradiation

Patients undergo radiotherapy 5 days a week